Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: An international, double-blind, randomised, placebo-controlled trial

The Lancet Oncology

Volumn 15, Issue 13, 2014, Pages 1460-1468

  Sestak, Ivana ^a   Singh, Shalini ^a   Cuzick, Jack ^a   Blake, Glen M ^b   Patel, Rajesh ^c   Gossiel, Fatma ^d   Coleman, Rob ^d   Dowsett, Mitch ^e   Forbes, John F ^f   Howell, Anthony ^g   Eastell, Richard ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g Genesis Breast Cancer Prevention Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; PLACEBO; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; NITRILE; TRIAZOLE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACNE; ACUTE SINUSITIS; ADULT; ALOPECIA; AMNESIA; ANGINA PECTORIS; ANXIETY; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BALANCE DISORDER; BONE DENSITY; BREAST CANCER; CANCER RISK; CATARACT; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; EMOTIONAL DISORDER; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GOITER; GYNECOLOGIC DISEASE; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; MIDDLE AGED; NITRILES; OSTEOPOROSIS; POSTMENOPAUSE; PROGNOSIS; TRIAZOLES;

EID: 84923679389     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71035-6     Document Type: Article

References (34)

1. Sowers MR, Zheng H, Jannausch ML, et al. Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. J Clin Endocrinol Metab 2010, 95:2155-2162.
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
3. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541. for the Fracture Intervention Trial Research Group.
4. Guise TA Bone loss and fracture risk associated with cancer therapy. Oncologist 2006, 11:1121-1131.
5. Leslie WD, Cowden EA, Maclean JP Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Nucl Med Commun 1995, 16:698-702.
6. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-1057.
7. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
8. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005, 23:5126-5137.
9. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
10. Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20:1489-1498.
11. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391.
12. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014, 383:1041-1048.
13. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012, 13:275-284.
14. GE Medical systems. DPX series operator's manual. GE Medical systems, 1998.
15. Kelly TL Bone mineral density reference databases for American men and women. J Bone Miner Res 1990, 5(suppl 1):S249.
16. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998, 8:468-489.
17. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008, 93:861-868.
18. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975.
19. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
20. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
21. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, 1. CD004523.
22. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012, 97:2272-2282.
23. Coleman RE Effect of anastrozole on bone mieral density and bon fractures: results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Eur J Cancer Suppl 2004, 2:140. abstr 289.
24. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
25. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127.
26. Goss PE, Hershman DL, Cheung AM, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol 2014, 15:474-482.
27. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013, 24:398-405.
28. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012, 118:1192-1201.
29. Llombart A, Frassoldati A, Paija O, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012, 12:40-48.
30. Sergi G, Pintore G, Falci C, et al. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. J Bone Miner Metab 2012, 30:461-467.
31. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011, 22:2546-2555.
32. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002, 11:614-621.
33. Vico L, Zouch M, Amirouche A, et al. High-resolution pQCT analysis at the distal radius and tibia discriminates patients with recent wrist and femoral neck fractures. J Bone Miner Res 2008, 23:1741-1750.
34. Kazakia GJ, Burghardt AJ, Link TM, Majumdar S Variations in morphological and biomechanical indices at the distal radius in subjects with identical BMD. J Biomech 2011, 44:257-266.